PV QA 1 - Poster Viewing Q&A 1
Purpose/Objective(s): The aim of this study was to evaluate the efficacy and safety of apatinib, an oral VEGFR2 inhibitor, with or without radiotherapy in the treatment of advanced/recurrent esophageal squamous cell carcinoma patients who failed from one or more lines of therapy.
Materials/Methods: The advanced or recurrent esophageal squamous cell carcinoma patients, who experienced one or more lines of therapy and treated with apatinib with or without radiotherapy from June 2015 to October 2017, were retrospectively reviewed. All eligible patients received continuous apatinib treatment until disease progression, death, or intolerable toxicity. Survival and toxicities outcome were evaluated by Kaplan-Meier method and according to NCI-CTC4.0.
Results: Forty-four patients were eligible. Patients characteristics were: median age 62 yrs, male/female 77.3/22.7%, ECOG PS 0/1/≥2 18.2/68.2/13.6%. 29 patients (65.9%) received 500 mg daily of apatinib, 7 patients received 250mg, 6 received 425mg and 2 received 750 mg daily. Dose modification occurred in 9 (20.5%) pts (reduction 5/11.4%; rise 4/9.1%). Twenty-seven（61.4%） patients received intensity modulated radiation therapy to primary tumor or metastatic sites. The best ORR and DCR were 34.1% and 77.3%, respectively. The median PFS and OS were 3.87 (95%CI, 3.07–4.88) and 5.93 (95%CI, 4.98–6.89) months, respectively. The toxicities associated with apatinib treatment was generally acceptable with 13 (29.5%) patients developed grade 3/4 toxicity. The most common adverse events in this study were hypertension(31.8%), hand-foot syndrome(27.2%), proteinuria(20.5%), fatigue (18.2%) and mouth mucositis(9.1%).
Conclusion: Apatinib ± radiotherapy showed promising efficiency with tolerable toxicity for advanced/recurrent esophageal squamous cell carcinoma patients who failed from one or more lines of therapy.
The asset you are trying to access is locked. Please enter your access key to unlock.